Skip to main content

Table 2 Current list of FDA-approved PD-L1 inhibitors along with indications, dosages, and bioassay for the PD-L1 expression

From: Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

PD-L1 inhibitors Indications Dosages and schedules PD-L1 bioassays PD-L1 cutoff References
Atezolizumab (MPDL3280A) NSCLC 1200 mg over 60 min q3 weeks Roche Ventana SP142 ≥ 50% TC or ≥ 10% IC [42]
UC    ≥ 5% IC [38]
ES-SCLC    N/A [44]
TNBC 840 mg q1 and 15   ≥ 1% IC [45]
Durvalumab (MEDI4736) UC 10 mg/kg over 60 min q2 weeks Roche Ventana SP263 ≥ 25% TC or ≥ 25% IC [59]
Unresectable stage III NSCLC    ≥ 1% TC [60]
Avelumab (MSB0010718C) MCC 10 mg/kg over 60 min q2 weeks N/A N/A [69]
RCC     [79]
  1. NSCLC non-small cell lung cancer, UC urothelial cancer, MCC Merkel cell carcinoma, TNBC triple-negative breast cancer, RCC renal cell carcinoma, ESSCLC extensive-stage small cell carcinoma, % IC percentage PD-L1 expressing tumor-infiltrating immune cells of any intensity of the tumor area, % TC percentage of PD-L1 expressing tumor cells of any intensity